Adma Biologics (ADMA) Short-term Investments (2014 - 2017)

Adma Biologics' Short-term Investments history runs 4 years deep, the most recent figure standing at $1.5 million for Q4 2017.

• Quarterly Short-term Investments fell 72.17% year-over-year to $1.5 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $1.5 million (down 72.17% YoY) and the FY2017 annual result came in at $1.5 million, down 72.17% from the prior year.
• Short-term Investments was $1.5 million for Q4 2017 at Adma Biologics, up from $245000.0 in the prior quarter.
• Across five years, Short-term Investments topped out at $6.4 million in Q4 2015 and bottomed at $245000.0 in Q1 2017.
• A 4-year average of $3.6 million and a median of $4.7 million in 2014 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2015 — Short-term Investments soared 36.87% — and 2017, when it plunged 72.17%.
• Adma Biologics' Short-term Investments stood at $4.7 million in 2014, then jumped by 36.87% to $6.4 million in 2015, then fell by 15.36% to $5.4 million in 2016, then plunged by 72.17% to $1.5 million in 2017.
• Business Quant data shows ADMA's Short-term Investments at $1.5 million in Q4 2017, $245000.0 in Q1 2017, and $5.4 million in Q4 2016.